Physician profile
Michael R Pate
NPI 1427245612
$3,049.67
in general payments reported to CMS, 2019-2025
14 companies · $839 in 2025
The $839 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $233 · 2021: $304 · 2022: $410 · 2023: $440 · 2024: $619 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803 · Entertainment: $95.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.21 |
| Entertainment | $95.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,147.15 | 2022-2025 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $866.16 | 2019-2025 | Precision7, Total30, Rocklatan |
| Johnson & Johnson Vision Care, INC. | $184.46 | 2022-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $153.53 | 2019-2021 | |
| Glaukos Corporation | $135.38 | 2024 | Ce-Marked Kxla System |
| Optos, INC. | $95.18 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $94.78 | 2020-2023 | |
| Abbvie INC. | $86.73 | 2022-2025 | |
| Coopervision INC. | $74.24 | 2023-2024 | Clariti Contact Lens, Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $72.46 | 2020 | |
| Shire North American Group INC | $65.96 | 2019 | |
| Alcon Research LLC | $29.72 | 2019 | |
| Allergan, INC. | $24.74 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $19.18 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.